Results 221 to 230 of about 9,794,717 (361)

Global and regional temporal changes in cross‐country inequalities of site‐specific osteoarthritis burden, 1990–2021

open access: yesArthritis Care &Research, Accepted Article.
Objective This study examined the global and regional temporal changes in cross‐country inequalities of site‐specific osteoarthritis (OA) burden from 1990 to 2021. Methods Age‐standardized years lived with disability rate for site‐specific OA across 204 countries/territories were obtained from the Global Burden of Diseases Study (GBD) 2021.
Haowei Chen   +14 more
wiley   +1 more source

Heterogeneity of Rheumatoid Arthritis‐Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations with Disease Outcomes

open access: yesArthritis Care &Research, Accepted Article.
Objective We aimed to identify unique disease trajectories within rheumatoid arthritis‐associated interstitial lung disease (RA‐ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes. Methods We performed a cohort study of RA‐ILD within the Veterans Health Administration from 1999‐2021. RA‐ILD patients were
Bryant R. England   +9 more
wiley   +1 more source

Virtual or in‐person: does it matter? Comparing pain, function, quality of life, self‐efficacy and physical function outcomes of virtual, hybrid and in‐person GLA:D Canada participants

open access: yesArthritis Care &Research, Accepted Article.
Objective This study aimed to determine if program format (in‐person, virtual, hybrid) results in differences in three‐month outcomes of pain, function, quality of life, self‐efficacy and chair stands in a hip/knee osteoarthritis management program. Methods A secondary analysis of the GLA:DTM Canada database was completed.
Jill Van Damme   +7 more
wiley   +1 more source

Considerations for Issues of Regression to the Mean and Contextual Effects in Clinical Trials for Pain in Rheumatic Diseases

open access: yesArthritis Care &Research, Accepted Article.
Recently, there has been growing discussion about how to best assess pain in clinical trials in rheumatic diseases. Reliable measurement of pain outcomes is essential for accurately determining the effectiveness of treatments. While pain intensity is the most common measure of change in pain trials, other pain‐related measures, such as pain ...
Yen T. Chen   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy